-0.73 (-2.86%)
Dilution Risk
Revenue
5.69 M
R&D Expenses
6.90 M
Operating CF
-10.94 M
Total Assets
30.88 M
Total Liabilities
9.27 M
Equity
21.61 M
D/E Ratio
12,345
Cash Position
16.38 M
Monthly Burn
3.65 M
Runway
3.1 mo
Burn Trend
SEC Filing
May 14, 2026locked
| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology |
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CUE-101 Small molecule | Head and Neck Squamous Cell Carcinoma | Phase 2 | NCT07172256 | 19% | $395M | NOT YET_RECRUITING | 30 | - | - | Feb 1, 2031 | - | LOW May 24, 2026 |
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
CUE-101 | HPV+ head and neck squamous cell carcinoma | Phase 1 | 2025-07-17 | |||
CUE-101 | HPV+ head and neck squamous cell carcinoma | Phase 1 | 2025-07-17 | |||
CUE-101 | HPV+ head and neck squamous cell carcinoma | Phase 1 | 2025-07-17 |
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-07-17 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-07-17 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-07-17 | 0.00 | 0 | - | - | - | - | - | - | ||||
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Cue Biopharma has announced a transition in its board of directors, with the resignation of four independent members and the appointment of Daniel Camardo and Viola Meehan. This change is part of the company's strategic growth as it aims to enhance its capabilities for late-stage clinical activities. The new directors bring extensive experience in biopharma and finance, which is expected to support Cue's mission in developing therapies for immunological disorders.
Read more →Cue Biopharma, a clinical-stage therapeutics company, will present at the Jefferies Global Healthcare Conference on June 3, 2026. CEO Shao-Lee Lin will discuss the company's innovative therapies aimed at treating immunological disorders. The presentation will be available via a live audio webcast, which will be archived for 90 days.
Read more →Cue Biopharma reported its first quarter 2026 financial results, revealing significant progress in its pipeline and strategic direction. Among the highlights, the company secured an exclusive license for CUE-221 aimed at allergic diseases and hosted a virtual R&D day focusing on its innovative CUE-401 program for autoimmune treatment. Financially, Cue reported an increase in revenue and completed a successful private placement, bolstering its operational capacity. New CEO Shao-Lee Lin emphasizes the company's mission to deliver transformative therapies in the immunology sector.
Read more →Cue Biopharma announced the granting of inducement equity awards to seven new employees, including CEO Shao-Lee Lin. The awards were part of the 2026 Inducement Stock Incentive Plan and were approved by independent directors. Dr. Lin received stock options and restricted stock units, while other employees received similar grants. The company focuses on developing therapies for immunological disorders.
Read more →Cue Biopharma announced the granting of inducement equity awards to seven new employees, including its new CEO, Dr. Shao-Lee Lin. The awards, approved by independent directors, include stock options and restricted stock units. This move is part of the company's strategy to attract talent as it advances its portfolio of therapies for immunological disorders.
Read more →Cue Biopharma has announced an exclusive license agreement with Ascendant Health Sciences for the anti-IgE monoclonal antibody Ascendant-221, aimed at treating allergic diseases. This move positions Cue as a clinical-stage company with innovative therapies targeting autoimmune and inflammatory disorders. Ascendant-221 is currently under evaluation in a Phase 2 clinical trial for chronic spontaneous urticaria, with plans for Cue to initiate a global Phase 2b trial in food allergies following the completion of the ongoing study. The agreement includes a $15 million upfront fee and potential future payments that could total up to $676.5 million.
Read more →Cue Biopharma announced a $30 million private placement financing agreement with accredited investors. This funding is intended to enhance the company's clinical pipeline, including the acquisition and development of its lead asset, Ascendant-221. The PIPE financing is set to close around May 4, 2026, subject to customary conditions. Additionally, the financing includes pre-funded warrants and common stock warrants, which require stockholder approval for execution.
Read more →Cue Biopharma has appointed Dr. Shao-Lee Lin as the new CEO, President, and Board Director to spearhead its transformation into a clinical-stage company. Dr. Lin brings over 25 years of biopharmaceutical experience and is expected to advance the company's clinical pipeline and goals, particularly regarding CUE-401, a potential treatment for autoimmune diseases. The company also indicates ongoing development of CUE-401 and additional programs aimed at significant near-term milestones in treatment options for allergic diseases, with a new Phase 2 program to be detailed in a future release.
Read more →Cue Biopharma has announced a 1-for-30 reverse stock split to increase its stock price and comply with Nasdaq listing requirements. This decision was approved by stockholders during the recent Annual Meeting. The split will reduce the total number of outstanding shares significantly while not affecting the company's authorized shares. The company continues to develop its innovative therapeutic biologics.
Read more →Cue Biopharma announced that it will present new preclinical data on its lead candidate CUE-401 at IMMUNOLOGY2026. The data highlights CUE-401's potential to induce antigen-specific T regulatory cells, suggesting promising therapeutic applications for autoimmune diseases. The candidate features a novel bifunctional design combining TGF-beta and IL-2 to enhance immune regulation. While the presentation could enhance visibility, Cue Biopharma faces ongoing financial and operational challenges as it develops its innovative therapies.
Read more →Cue Biopharma has announced a $7.5 million preclinical milestone payment from Boehringer Ingelheim after the selection and approval of its first compound for lead optimization. This milestone validates the potential of CUE-501 for targeted depletion of specific B cells in autoimmune diseases. The company also stands to earn up to $337.5 million in additional milestone payments.
Read more →Cue Biopharma has appointed Lucinda Warren as interim CEO following Usman Azam's resignation. Warren, who has significant experience in the biopharmaceutical sector, aims to advance the company's lead asset, CUE-401, into clinical trials by the second half of 2026. The board expresses confidence in her leadership during this transition period.
Read more →Cue Biopharma will host a virtual R&D Day on April 7, 2026, featuring discussions on CUE-401, its lead asset for autoimmune diseases. Key Opinion Leaders Richard DiPaolo, PhD, and Jonathan Kay, MD, will present alongside company management. The event will include a live Q&A session and will be available for later viewing.
Read more →Cue Biopharma reported its fourth quarter and full year 2025 financial results, highlighting advancements in the development of CUE-401 for autoimmune diseases. The company secured a strategic collaboration with ImmunoScape, which includes upfront payments totaling $15 million. Despite increased R&D expenses, Cue Biopharma is optimistic about its future prospects and plans to host a Virtual R&D Day to discuss CUE-401.
Read more →Cue Biopharma is set to present new in vitro data for its lead asset, CUE-401, at the World Immune Regulation Meeting in Davos, Switzerland. The data highlight CUE-401's potential to modulate immune responses in autoimmune and inflammatory diseases. The presentation will be delivered by Natasha M. Girgis, showcasing the therapeutic effects of TGF-beta in controlling proinflammatory pathways.
Read more →Cue Biopharma announced promising preclinical safety and tolerability data for CUE-401, its lead asset for autoimmune diseases. The studies showed that CUE-401 was well tolerated, with no adverse events reported. The company plans to file an investigational new drug (IND) application in the coming months, reinforcing the therapeutic potential of this innovative biologic.
Read more →Cue Biopharma has appointed Lucinda Warren as Chief Financial and Business Officer, effective February 9, 2026. Warren, who has been with the company as Chief Business Officer since September 2024, will leverage her extensive experience in the pharmaceutical industry to support the company's growth and advance its lead autoimmune asset, CUE-401, toward clinical trials.
Read more →Cue Biopharma has announced the pricing of a public offering of 35,714,286 shares of common stock, expected to raise around $10 million. The offering includes warrants and is set to close on December 22, 2025, pending customary conditions. H.C. Wainwright & Co. is the sole book-running manager for the offering.
Read more →Cue Biopharma, a clinical-stage biopharmaceutical company, has announced a proposed public offering of its common stock and accompanying warrants. The offering is underwritten by H.C. Wainwright & Co. and is subject to market conditions. The company is utilizing its effective shelf registration statement for this offering, and while they may grant underwriters an option to purchase additional shares, there are notable risks including their financial stability and R&D challenges. Stakeholders are advised that forward-looking statements may not be realized as there are uncertainties involved.
Read more →Cue Biopharma reported its third quarter 2025 financial results, highlighting a decrease in collaboration revenue but significant progress in advancing its Immuno-STAT® platform. The company aims to address unmet needs in autoimmune disease treatment with its lead asset, CUE-401. Despite some financial challenges, Cue Biopharma is positioned for future growth.
Read more →Cue Biopharma and ImmunoScape have announced a strategic collaboration to develop an innovative cell therapy approach for solid tumors. This partnership will utilize Cue's Immuno-STAT T-cell engagers and ImmunoScape's proprietary TCRs in a Seed-and-Boost immunotherapy strategy. The collaboration aims to improve anti-tumor activity while minimizing systemic immune activation, potentially setting a new standard of care.
Read more →Cue Biopharma has appointed Dr. Usman Azam as the new CEO, transitioning from Daniel Passeri, who will become a Strategic Advisor. This leadership change aims to enhance the company's focus on autoimmune diseases, particularly with its lead candidate CUE-401. Dr. Azam brings over 25 years of experience in drug development, which is expected to drive the company's growth.
Read more →Cue Biopharma will participate in a fireside chat at the Cantor Global Healthcare Conference from September 3-5, 2025. The company will provide updates on its Immuno-STAT® platform and discuss its lead autoimmune asset, CUE-401. The presentation will be led by CEO Daniel Passeri and will be available via webcast.
Read more →Cue Biopharma has launched an investigator-sponsored trial for CUE-102, targeting recurrent glioblastoma multiforme (rGBM). The Phase 1b trial aims to assess the drug's tolerability and clinical efficacy in patients experiencing their first recurrence. The trial is led by Dr. David A. Reardon at the Dana-Farber Cancer Institute, focusing on the activation of WT1-specific T cells to improve treatment outcomes.
Read more →Cue Biopharma reported its second quarter 2025 financial results, highlighting recent achievements such as positive FDA feedback on its pre-IND briefing for CUE-401 and a new collaboration with Boehringer Ingelheim for CUE-501. The company raised approximately $20 million through a public offering and shared encouraging clinical data indicating CUE-101's potential as a new standard of care in treating HPV+ head and neck cancer. Despite successes, the company faced ongoing financial challenges with significant net losses reported.
Read more →Cue Biopharma has reported a complete response in a patient with recurrent metastatic HPV+ head and neck cancer during a Phase 1 trial of CUE-101 combined with pembrolizumab. The trial data indicates a 50% overall response rate, with significant tumor reductions and durable stable disease observed in participants. The company believes this therapy could establish a new standard of care in treating this cancer type.
Read more →Cue Biopharma has provided an update on CUE-101, its leading clinical asset, presented by Dr. Dimitrios Colevas at the DAVA 4th Hawaii Global Summit. The Phase 1 trial results show a 50% overall response rate in patients with HPV+ recurrent metastatic head and neck squamous cell carcinoma. Additionally, the 12-month survival rate stands at 88%, significantly better than historical data. The company believes these results position CUE-101 as a potential breakthrough therapy.
Read more →Cue Biopharma has received positive feedback from the FDA regarding its Pre-IND briefing for CUE-401, a novel bispecific fusion protein aimed at treating autoimmune diseases. The FDA reviewed the trial design and safety monitoring plan, allowing the company to proceed with its IND submission. CUE-401 aims to induce and expand regulatory T cells, offering a potentially disruptive approach in the field.
Read more →Cue Biopharma, Inc. has announced its 2025 Stock Incentive Plan aimed at advancing stockholder interests. The plan is designed to attract, retain, and motivate significant contributors to the company through various equity ownership and performance-based incentives. Eligible participants include employees, officers, directors, and consultants, with a total of up to 18,338,461 shares available for awards. The Board of Directors will oversee the administration of the plan, which allows for flexibility in granting various types of awards.
Read more →Cue Biopharma has reported strong first quarter 2025 results, highlighting a strategic collaboration and license agreement with Boehringer Ingelheim, securing $12 million upfront. The company raised approximately $20 million in additional capital and regained rights to its lead program, CUE-401. However, Cue Biopharma continues to face financial challenges, posting a net loss of $12.3 million, underscoring its need for ongoing funding to support future operations. A virtual event featuring key opinion leaders in immunology is scheduled for May 15, 2025, to discuss recent advancements and data from their product pipeline.
Read more →Cue Biopharma, Inc. reported its financial results for the first quarter of 2025, highlighting a strategic collaboration with Boehringer Ingelheim that includes a $12 million upfront payment. The company raised approximately $20 million in a follow-on capital raise and regained worldwide rights for its lead autoimmune program, CUE-401. However, the revenue reported for the quarter was $0.4 million, a decline compared to the previous year, and the firm continues to face operating losses, indicating that financial challenges remain.
Read more →Cue Biopharma announced a virtual investor event scheduled for May 15, 2025, to discuss its innovative biologics platform. The event will feature key opinion leaders and provide insights into the company's clinical trials, including data on its lead candidate CUE-401. Additionally, Cue Biopharma will outline its ongoing work on various biologics aimed at autoimmune diseases and cancer. The company aims to enhance immune response treatments through its proprietary Immuno-STAT technology.
Read more →Cue Biopharma, a clinical-stage biopharmaceutical company, announced its participation in the Citizens Life Sciences Conference on May 7-8, 2025, in New York. During a fireside chat, Cue will present updates on its Immuno-STAT™ platform, including the CUE-100 series, CUE-401, and CUE-501, which is in collaboration with Boehringer Ingelheim. The company aims to engage and modulate T cells to address autoimmune diseases and cancer, leveraging its innovative therapeutic biologics. The event will be available via live and archived webcast for 30 days on their website.
Read more →Cue Biopharma, Inc. announced a business update call and webcast scheduled for April 15, 2025. The company, which specializes in developing therapeutic biologics for cancer and autoimmune diseases, aims to engage and modulate T cells directly in patients. The webcast will be available live and archived for 30 days on their website. Cue Biopharma operates from Boston and has a management team with significant expertise in immunology and protein engineering.
Read more →Cue Biopharma, a clinical-stage biopharmaceutical company, announced the pricing of a public offering aimed at raising approximately $20 million. This offering includes 13,530,780 shares of common stock and various warrants, with a combined price set at $0.79 per share. The funds raised are intended to support the company's development of its proprietary class of therapeutics targeting disease-specific T cells. The offering is expected to close by April 16, 2025, subject to customary closing conditions.
Read more →Cue Biopharma, a clinical-stage biopharmaceutical company, announced its fourth quarter and full year 2024 financial results, highlighting an increase in collaboration revenue and strategic appointments to its leadership team. Despite the progress, the company recorded significant net losses and decreased cash reserves, which raise concerns about its financial sustainability. The firm is focused on advancing its Immuno-STAT platform and has regained rights for CUE-401, which may enhance treatment options for autoimmune diseases.
Read more →Cue Biopharma, Inc. announced the grant of an inducement option award to its new interim chief development officer, Dr. Daniel Baker, in alignment with Nasdaq Listing Rule 5635(c)(4). This award includes an option to purchase 200,000 shares at an exercise price of $1.06 per share, equivalent to the closing price on November 25, 2024. The award will vest over two years with continued employment. Cue Biopharma focuses on developing innovative therapeutic biologics for cancer and autoimmune diseases.
Read more →Cue Biopharma, Inc. will participate in a fireside discussion at the Piper Sandler 36th Annual Healthcare Conference scheduled for December 3-5, 2024, in New York. During the event, CEO Daniel Passeri will present updates on the company's clinical and preclinical programs, as well as its strategic business objectives. The company's proprietary Immuno-STAT™ platform focuses on modulating disease-specific T cells to enhance treatment for cancer and autoimmune diseases. A webcast of the discussion will be available for those unable to attend live.
Read more →Cue Biopharma, a clinical-stage biopharmaceutical company, has announced the appointment of Dr. Daniel Baker as interim chief development officer, effective November 25, 2024. Dr. Anish Suri will transition to the role of principal research and immunology advisor. This organizational change aims to advance the company’s pipeline in oncology and autoimmune treatments. Dr. Baker brings over 20 years of drug development experience, contributing to the company’s mission to develop innovative immunotherapies.
Read more →Cue Biopharma, Inc. reported its financial results and business highlights for the third quarter of 2024. The company presented promising data from Phase 1 trials for its treatments CUE-101 and CUE-102, showing significant efficacy in cancer therapies. While revenues increased due to collaboration agreements, the company also experienced a net loss and a decrease in cash reserves. Cue Biopharma continues to advance its preclinical programs and aims for drug candidate selection in its autoimmune treatment initiatives.
Read more →Cue Biopharma, Inc. will participate in a fireside chat at the Stifel 2024 Healthcare Conference on November 19, 2024. The discussion will focus on updates related to its oncology and autoimmune disease programs, including recent Phase 1 clinical data for CUE-101 and CUE-102. The event highlights Cue Biopharma's commitment to developing its proprietary Immuno-STAT™ platform, which aims to enhance the body’s immune response safely. A live webcast of the event will be available, along with an archived version on the company's website.
Read more →Cue Biopharma presented updated positive data for its Phase 1 trials involving CUE-101 and CUE-102 at the SITC 39th Annual Meeting. The results showed a 46% objective response rate and 91.3% overall survival rate for CUE-101 in HPV+ recurrent/metastatic head and neck cancer. Additionally, CUE-102 achieved a 67% overall disease control rate in late-stage pancreatic cancer. Both therapies were reported to be well-tolerated without significant adverse events.
Read more →Cue Biopharma, Inc. has announced it will showcase its clinical assets, CUE-101 and CUE-102, at the Society for Immunotherapy of Cancer’s 39th Annual Meeting, scheduled for November 6-10, 2024, in Houston, Texas. The presentations will focus on innovative trials involving these drug candidates in treating certain cancers. The event will feature both oral and poster presentations delivered by leading experts in the field, highlighting Cue Biopharma's commitment to advancing its immuno-oncology platform.
Read more →Cue Biopharma has priced a public offering amounting to $12 million, involving over 11 million shares and accompanying warrants. The offering will close around September 30, 2024, pending standard conditions. Despite the positive outlook, the company faces challenges such as historical losses and a limited operational track record, which may affect investor confidence.
Read more →Cue Biopharma has appointed Lucinda Warren as Chief Business Officer, leveraging her extensive experience in strategic transactions and business development. Warren previously served at Johnson & Johnson, where she focused on business development in Neuroscience. Her expertise is expected to drive Cue Biopharma's initiatives post-restructuring and enhance collaboration opportunities. This strategic move aims to support the company's objectives in advancing their innovative immunotherapy platform.
Read more →Cue Biopharma announced that its management team will present at The Promise of Interleukin-2 Therapy Conference from September 4-7, 2024, in Paris. Presentations will cover preclinical data for the novel fusion protein CUE-401 and updates on oncology programs CUE-101 and CUE-102. These presentations aim to demonstrate the company's advancements in selectively targeting T cells to enhance safety and efficacy in treatments. The event underscores Cue Biopharma's commitment to developing innovative immunotherapeutics.
Read more →Cue Biopharma reported its financial results and business developments for Q2 2024, highlighting advancements in oncology and autoimmune programs. The data presented from the Phase 1 trials of CUE-101 and CUE-102 indicates promising efficacy in treating HPV+ recurrent/metastatic head and neck cancers. Collaboration revenue increased significantly year-over-year, while the company attempted to optimize its financial strategy by prioritizing certain research programs. However, Cue Biopharma continues to face challenges, including losses and a decrease in cash reserves compared to the previous year.
Read more →Cue Biopharma has announced a strategic focus on its autoimmune programs to enhance operational efficiencies and potential value creation. The company aims to reduce its workforce and operating expenses by approximately 25%, streamlining its resources while retaining oncology programs. With promising preclinical advancements in its autoimmune candidates such as CUE-401 and CUE-501, Cue Biopharma plans to extend its financial runway into mid-2025. The organizational restructuring is set to support the ongoing development of critical therapeutic opportunities in autoimmune diseases.
Read more →Cue Biopharma has announced updated data from its Phase 1 trial of CUE-101 for recurrent/metastatic HPV+ head and neck cancer, presenting findings at the 2024 ASCO Annual Meeting. The trial reported an overall response rate of 46% and a 12-month overall survival rate of 96% for patients in the first line of treatment. Additionally, CUE-101 demonstrated a median overall survival of 20.8 months in second-line patients, significantly outperforming historical benchmarks. The combination therapy of CUE-101 and KEYTRUDA was well-tolerated with manageable adverse events.
Read more →Cue Biopharma has announced its participation in two upcoming healthcare investor conferences in June 2024. The presentations will cover the company's clinical and preclinical progress in its oncology and autoimmune platforms. Anish Suri, Ph.D., president and chief scientific officer, will lead the discussions, showcasing the company's innovative Immuno-STAT™ platform for T cell modulation. These engagements demonstrate Cue Biopharma's ongoing efforts to promote its therapeutic advancements to potential investors.
Read more →Cue Biopharma has reported its financial results for the first quarter of 2024, highlighting significant advancements in their clinical programs. Notably, abstracts for both CUE-101 and CUE-102 have been accepted for presentation at the upcoming ASCO Annual Meeting. The company generated $1.7 million in collaboration revenue, a marked increase from the previous year, yet continues to face operating losses. Cue Biopharma also anticipates their cash reserves will sustain operations through the first quarter of 2025.
Read more →Cue Biopharma, a clinical-stage biopharmaceutical firm, announced its participation in the 20th PEGS Boston Summit, scheduled for May 13-17, 2024. The company will deliver two poster presentations, focusing on its Immuno-STAT technology aimed at targeting autoimmune diseases and enhancing T cell responses. Presentations will cover the efficacy of bispecific Immuno-STAT biologics and the broader implications of their T-cell engager platform. The event will also feature an overview of Cue's oncology assets, which have shown clinical anti-tumor activity.
Read more →Cue Biopharma, a clinical-stage biopharmaceutical firm, will participate in a fireside chat at The Citizens JMP Life Sciences Conference on May 14, 2024, to discuss its oncology and autoimmune disease strategies. CEO Daniel Passeri will present during the chat, which is set to take place from 12:00 to 12:25 p.m. ET. As part of its commitment to innovation, Cue Biopharma is focusing on its proprietary Immuno-STAT™ platform to develop selective biologics that engage disease-specific T cells directly in patients.
Read more →Cue Biopharma, Inc. has announced its participation in the upcoming 2024 ASCO Annual Meeting, where it will present findings from Phase 1 trials of its lead biologics, CUE-101 and CUE-102. The oral abstract will focus on CUE-101 in recurrent/metastatic head and neck cancer, while a poster will feature CUE-102 for WT1-positive cancers. Additional insights about clinical progress will be shared during a Business Update call after the event. The presentations highlight Cue Biopharma's innovative immunotherapy approach.
Read more →Cue Biopharma reported its fourth quarter and full year 2023 financial results, showcasing positive developments in its clinical trials for CUE-101 and CUE-102 while receiving guidance from the FDA on potential registrational trials. Notably, CUE-101 showed improved patient outcomes in HPV+ cancers and CUE-102 demonstrated effectiveness in late-stage cancers. The company's collaboration revenue increased significantly due to a partnership with Ono Pharmaceutical. However, operational expenses were high, resulting in a substantial net loss, and cash reserves decreased compared to the previous year.
Read more →Cue Biopharma has announced that its lead asset, CUE-101, will be featured at the 2024 Multi-disciplinary Head and Neck Cancers Symposium. Dr. Alexander Dimitrios Colevas will present data from an ongoing Phase 1 trial, highlighting impressive results such as a 47% overall response rate for patients treated with CUE-101 and pembrolizumab. In addition, the median overall survival for patients treated with CUE-101 monotherapy is reported at 20.8 months, compared to significantly lower historical averages. The symposium takes place in Phoenix, Arizona, from February 29 to March 2, 2024.
Read more →Cue Biopharma, Inc. will present a corporate update at the Oppenheimer 34th Annual Healthcare Life Sciences Conference, scheduled for February 13-14, 2024. CEO Dan Passeri will discuss developments from its lead clinical programs, including CUE-101 and CUE-102, along with the preclinical autoimmune program in collaboration with Ono Pharmaceutical. The presentation will also cover key milestones for 2024 and market opportunities. Interested parties can access the live and archived webcast via the company's website.
Read more →Cue Biopharma, a clinical-stage biopharmaceutical company, will participate in a virtual fireside chat at the JMP Securities Hematology and Oncology Summit on December 5-6, 2023. The discussion will focus on recent data highlights from its lead clinical programs, CUE-101 and CUE-102, and address market opportunities and milestones anticipated for 2024. The event will feature CEO Daniel Passeri and include a live webcast accessible for 30 days post-event.
Read more →Cue Biopharma announced its third quarter 2023 financial results, highlighting significant advancements in its clinical trials. Positive data from Phase 1 trials of CUE-101 and CUE-102 showcased improved survival rates and disease control. The company reported a rise in collaboration revenue to approximately $2.1 million and increased research and development expenses. Despite a net loss of $11 million, Cue Biopharma remains optimistic about its future in immuno-oncology.
Read more →Cue Biopharma, Inc. announced it will present at three investor conferences in November, including the Stifel Healthcare Conference and the Jefferies London Healthcare Conference. The presentations will include a corporate overview and recent data from its lead clinical programs, CUE-101 and CUE-102. CEO Daniel Passeri will lead the discussions, showcasing the company's novel class of T cell engagers. Webcasts of the presentations will be available on the company's website.
Read more →Cue Biopharma has reported positive results from its Phase 1 trials of CUE-101 and CUE-102 at the SITC 2023 conference. CUE-101 demonstrated a 47% overall response rate and a median overall survival of 20.8 months for previously treated head and neck cancer patients. Meanwhile, CUE-102 exhibited a favorable disease control rate of 75%-80% with no dose-limiting toxicities so far. The outcome highlights the potential of these therapies in addressing significant unmet medical needs in cancer treatment.
Read more →Cue Biopharma has announced two poster presentations at the upcoming Society for Immunotherapy of Cancer's 38th Annual Meeting, showcasing its Immuno-STAT platform and lead candidates CUE-101 and CUE-102. The conference is set to take place from November 1-5, 2023, in San Diego, California. The presentations will detail findings from phase 1 studies targeting HPV16+ head and neck cancer and WT1-positive recurrent/metastatic cancers. Additionally, the posters will be accessible to attendees virtually and will also be available on the company's website after the event.
Read more →Cue Biopharma has completed patient enrollment in its Phase 1 clinical trial evaluating CUE-101, an interleukin-based biologic, in combination with KEYTRUDA for HPV+ head and neck cancer patients. The treatment has shown promising results, exceeding historical efficacy rates previously recorded with KEYTRUDA alone. The company plans to present updated trial data at the upcoming SITC Annual Meeting and discusses potential regulatory paths with the FDA. This positive data reinforces Cue Biopharma's confidence in its Immuno-STAT platform and its ability to address unmet clinical needs.
Read more →Cue Biopharma, Inc. has provided its financial and business updates for Q2 2023, reporting positive advancements in clinical trials, particularly for its lead candidate CUE-101. The company noted an increase in collaboration revenue, largely due to partnerships with Ono Pharmaceutical Co., Ltd. Despite the promising data, Cue Biopharma faces challenges with escalating research and development expenses and a continuing operating loss. The firm expects its cash reserves to sustain operations through Q3 2024.
Read more →Cue Biopharma announced its participation in the FOCIS 2023 Annual Meeting, where it will present its Immuno-STAT platform and the bispecific protein CUE-401. The oral presentation will detail the efficacy and safety profiles of CUE-101, the company's lead candidate targeting tumor-specific T cells for enhanced cancer treatment. Additionally, the company is collaborating with Ono Pharmaceutical on CUE-401, designed to induce regulatory T cells for autoimmune diseases. The presentations highlight the company's focus on innovative therapies in immuno-oncology and autoimmune conditions.
Read more →Cue Biopharma, Inc. announced it will host an investor call on June 14, 2023, to discuss updates on its clinical trials. The call will cover the progress of its lead drug candidate, CUE-101, and other candidates from its CUE-100 series, which target HPV16+ recurrent/metastatic head and neck squamous cell carcinoma and WT1-positive cancers. The company aims to inform investors about its ongoing Phase 1 trials and recent data shared at the ASCO Annual Meeting.
Read more →Cue Biopharma, Inc. will present at the Jefferies 2023 Global Healthcare Conference from June 7-9 in New York. The presentation will feature updates on their lead asset CUE-101 for treating recurrent/metastatic HPV16+ head and neck cancer and details on CUE-102 for WT1-positive cancers and CUE-401 for autoimmune diseases. The company is focused on developing biologics that engage and modulate disease-specific T cells directly within the patient's body.
Read more →Cue Biopharma has presented favorable data from its ongoing Phase 1 trials of CUE-101 for treating recurrent/metastatic HPV+ head and neck squamous cell carcinoma. The results indicate significant tumor regression in a substantial portion of patients and promising overall survival rates compared to current standard therapies. The efficacy appears enhanced when CUE-101 is used in combination with pembrolizumab, with investigators optimistic about potential pathways for further development and registration. The positive outcomes underline the potential of CUE-101 as an innovative treatment in this area of unmet medical need.
Read more →Cue Biopharma, Inc. has announced that it will present at the 2023 American Society of Clinical Oncology Annual Meeting in Chicago, highlighting its lead clinical candidate CUE-101. This candidate is designed to treat recurrent or metastatic head and neck squamous cell carcinoma associated with HPV16. An Investor Update call is scheduled for June 14, 2023, to discuss the clinical progress and data from the ASCO presentation. The session is poised to share insights on the promising immunotherapy approach developed by the company.
Read more →Cue Biopharma reported its first quarter 2023 financial results, showcasing a decrease in collaboration revenue primarily due to the completion of a prior research phase. The company achieved significant milestones, including the acceptance of an abstract for CUE-101 at the upcoming ASCO Annual Meeting and a new strategic collaboration with Ono Pharmaceutical for CUE-401. Appointments to the board of directors and scientific advisory board were also made. Despite these positive developments, Cue Biopharma noted a decline in cash reserves compared to the previous year, raising potential concerns about funding operations in the future.
Read more →Cue Biopharma, a clinical-stage biopharmaceutical company, will present at the JMP Securities Life Sciences Conference on May 15, 2023. During the event, the company plans to discuss its clinical trials for its lead oncology drug candidates, CUE-101 and CUE-102. Cue Biopharma aims to engage and modulate T cells using its unique Immuno-STAT platform, highlighting its commitment to advancing immunotherapy. The management team brings considerable expertise in the field, reflecting its strong position in the biopharma sector.
Read more →Cue Biopharma has appointed Dr. Pamela D. Garzone to its Board of Directors, bringing over 25 years of experience in drug development. Her background includes strategic and regulatory leadership across various therapeutic areas, particularly in immuno-oncology. This addition is anticipated to bolster Cue Biopharma's strategic planning as it seeks to advance its clinical and preclinical pipeline. Dr. Garzone expressed enthusiasm about contributing to the company’s innovative approach in treating cancer and autoimmune diseases.
Read more →Cue Biopharma has appointed Patrick Verheyen, an industry veteran with over 35 years of experience, to its Board of Directors. Verheyen previously held significant roles at Janssen Pharmaceutical Companies and is expected to guide Cue Biopharma's strategic initiatives as it develops its clinical drug candidates, CUE-101 and CUE-102. The company specializes in a novel class of injectable biologics aimed at modulating disease-specific T cells. His extensive background in business development and mergers & acquisitions will support the company's goals to enhance its innovative platform in immunotherapy for cancer and autoimmune diseases.
Read more →Cue Biopharma reported strong advancements in its clinical pipeline and financial status for 2022. The company received FDA approval for its CUE-102 drug and Fast Track Designation for CUE-101, along with displaying positive clinical data at a recent meeting. However, it experienced a significant decline in collaboration revenue and a rise in operational losses compared to the previous year. Cue Biopharma also engaged in a partnership with Ono Pharmaceutical to advance its CUE-401 asset, demonstrating ongoing commitment to its research and development goals.
Read more →Cue Biopharma, Inc. is set to present at two prominent investor healthcare conferences in March 2023. The company will highlight recent advancements in its IL-2-based CUE-100 biologics series, particularly focusing on CUE-101 for treating HPV+ recurrent/metastatic head and neck cancer and CUE-102 for Wilms' Tumor 1 positive cancers. Additionally, Cue Biopharma will discuss its partnership with Ono Pharmaceutical to advance its autoimmune treatment candidate, CUE-401. Webcasts of the presentations will be accessible on the company's website.
Read more →Cue Biopharma has announced a strategic collaboration and option agreement with Ono Pharmaceutical for CUE-401, a bispecific protein aimed at inducing regulatory T cells to treat autoimmune and inflammatory diseases. Under the agreement, Ono will fund all research activities related to CUE-401 and pay Cue Biopharma an upfront payment. The collaboration includes potential milestone payments and grants Ono worldwide rights to develop the therapy, while Cue retains a 50% co-development and co-commercialization right in the U.S. This partnership is a significant step for Cue Biopharma toward advancing CUE-401 toward clinical trials.
Read more →Cue Biopharma, a clinical-stage biopharmaceutical company, has appointed Dr. Rafi Ahmed to its Scientific Advisory Board. Dr. Ahmed, recognized for his substantial contributions to immunology, will provide insights directly related to the firm's cancer therapies focused on disease-specific T cells. His involvement is expected to enhance the company's capabilities in developing targeted treatments for cancer, as highlighted by their existing clinical candidates, CUE-101 and CUE-102. The announcement reflects Cue's commitment to leveraging expertise in advancing its innovative therapeutic approaches.
Read more →Cue Biopharma announced that its therapeutic Immuno-STAT biologics platform will be featured at the 67th Biophysical Society Annual Meeting. This presentation, conducted in collaboration with Dr. Michael Dustin's lab at Oxford University, highlights the mechanism of action by activating disease-specific T cells. The company reported positive data supporting the efficacy of its CUE-100 series in targeting T cells while minimizing off-target effects. Cue Biopharma aims to share further clinical progress related to its lead candidate, CUE-101, designed for HPV+ head and neck cancer.
Read more →Cue Biopharma, a clinical-stage biopharmaceutical company, announced that its President and Chief Scientific Officer, Anish Suri, Ph.D., will participate in two scientific conferences in February 2023. At these events, Suri will present on the company's Immuno-STAT™ platform, which is designed to engage disease-specific T cells. Both presentations will focus on innovative therapies aimed at improving cancer treatment through targeted immunotherapy.
Read more →Cue Biopharma has announced the promotion of Matteo Levisetti, M.D., to Chief Medical Officer effective January 17, 2023. This decision follows the transition of Kenneth Pienta, M.D., into a clinical advisory role. Levisetti has previously served as the senior vice president of clinical development at Cue Biopharma and is expected to leverage his extensive experience to advance the company's oncology pipeline. The leadership transition is considered a strategic move to build on the foundations laid by Pienta during his tenure.
Read more →BOSTON, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate tumor-specific T cells directly within the patient’s body, announced today t
Read more →Cue Biopharma Announces $30 Million Private Investment in Public Equity (PIPE) Financing BOSTON, Nov. 14, 2022 (GLOBE NEWSWIRE) Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage a
Read more →BOSTON, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate tumor-specific T cells directly within the patient’s body, reported today th
Read more →Overall response rate (ORR) of 40% and a clinical benefit rate (CBR) of 70% observed to date in first line (1L) recurrent/metastatic HNSCC patients treated with CUE-101 at the recommended Phase 2 dose and pembrolizumab. Median overall survival (mOS) approaching greater than 12 m
Read more →BOSTON, Nov. 09, 2022 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate tumor-specific T cells directly within the patient’s body, announced today t
Read more →BOSTON, Oct. 05, 2022 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate tumor-specific T cells directly within the patient’s body, announced today t
Read more →BOSTON, Oct. 04, 2022 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics designed to selectively engage and modulate tumor-specific T cells directly within the patient’s body, announce
Read more →BOSTON, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate tumor-specific T cells directly within the patient’s body, announced today
Read more →BOSTON, Aug. 22, 2022 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate tumor-specific T cells directly within the patient’s body, announced today t
Read more →BOSTON, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate tumor-specific T cells directly within the patient’s body, reported today se
Read more →BOSTON, July 11, 2022 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate tumor-specific T cells directly within the patient’s body, announced today t
Read more →BOSTON, June 13, 2022 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate targeted T cells directly within the patient’s body, announced today that it
Read more →BOSTON, June 01, 2022 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate targeted T cells directly within the patient’s body, announced today that it
Read more →BOSTON, May 26, 2022 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate targeted T cells directly within the patient’s body, announced today it will
Read more →Company to initiate Phase 1 dose escalation and expansion trial for the treatment of Wilms’ Tumor 1 (WT1) positive recurrent/metastatic cancers Starting dose of 1 mg/kg expected to reduce time and cost of dose escalation phase of trial, supporting development efficiency of CUE-1
Read more →BOSTON, May 10, 2022 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate targeted T cells directly within the patient’s body, today reported first qua
Read more →CAMBRIDGE, Mass., March 10, 2022 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate targeted T cells directly within the patient’s body, announced to
Read more →CAMBRIDGE, Mass., March 02, 2022 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics designed to selectively engage and modulate targeted T cells directly within the patient’s body, ann
Read more →Presentation provides mechanistic insights and progress update on collaboration with the laboratory of Michael Dustin at the University of Oxford to study the role of IL-2 in the T cell immunological synapse formation using the IL-2 based CUE-100 series CAMBRIDGE, Mass., Feb. 15
Read more →Early data in the combination study of CUE-101 and KEYTRUDA® (pembrolizumab) supports synergistic activity; of four patients treated in dose escalation in the 2mg/kg and RP2D 4mg/kg cohorts, two have partial responses (1 confirmed and 1 unconfirmed) and two are manifesting reduct
Read more →CAMBRIDGE, Mass., Jan. 20, 2022 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectively engage and modulate targeted T cells directly within the patient’s body, ann
Read more →Selective activation and expansion of Wilms’ Tumor 1 (WT1)-specific cytotoxic CD8+ T cells in preclinical models supports the potential for clinical activity treating WT1-expressing cancers Further advancement of CUE-102 enhances pipeline development and demonstrates modularity
Read more →CAMBRIDGE, Mass., Dec. 15, 2021 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells directly within the patient’s body, announced to
Read more →CAMBRIDGE, Mass., Dec. 06, 2021 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectively engage and modulate targeted T cells directly within the patient’s body, ann
Read more →CAMBRIDGE, Mass., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectively engage and modulate targeted T cells within the patient’s body, announced to
Read more →Corporate Presentation Immune Responses, On Cue Nasdaq: CUE November 2021 Exhibit 99.1 Forward-Looking Statements Disclosure This presentation has been prepared by Cue Biopharma, Inc. ("we," "us," "our," "Cue" or the "Company") and is made for informational purposes only and d
Read more →Monotherapy data further enhances confidence in CUE-101 potential as single agent therapeutic in the refractory/metastatic human papillomavirus positive head and neck squamous cell carcinoma (HPV+ HNSCC) setting Early CUE-101 combination data with KEYTRUDA® (pembrolizumab) suppo
Read more →CAMBRIDGE, Mass., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells directly within the patient’s body, announced to
Read more →CAMBRIDGE, Mass., Oct. 04, 2021 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells directly within the patient’s body, announced to
Read more →Research demonstrates that platform technologies generate therapeutic molecules for selective delivery of immune activating signals, such as IL-2, to disease-relevant T cells, hence avoiding systemic activation of the broader immune compartment Publication details the peptide-HL
Read more →CAMBRIDGE, Mass., Sept. 21, 2021 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells directly within the body, announced today the i
Read more →CAMBRIDGE, Mass., Aug. 17, 2021 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells within the patient’s body, provided a business a
Read more →CAMBRIDGE, Mass., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectively engage and modulate targeted T cells directly within the patient’s body, ann
Read more →CAMBRIDGE, Mass., June 10, 2021 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectively engage and modulate targeted T cells directly within the patient’s body, ann
Read more →CAMBRIDGE, Mass., June 03, 2021 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectively engage and modulate targeted T cells directly within the patient’s body, ann
Read more →CAMBRIDGE, Mass., May 26, 2021 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectively engage and modulate targeted T cells directly within the patient’s body, anno
Read more →CAMBRIDGE, Mass., May 17, 2021 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells within the patient’s body, provided a business an
Read more →And Provides Interim Clinical Data Update Partial response data demonstrates activity of CUE-101 as monotherapy in patient with human papilloma virus positive recurrent/metastatic head and neck squamous cell carcinoma (HPV+ R/M HNSCC) The objective tumor response observed in th
Read more →CAMBRIDGE, Mass., May 06, 2021 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectively engage and modulate targeted T cells directly within the patient’s body, anno
Read more →Corporate Presentation Immune Responses, On Cue Nasdaq: CUE Oppenheimer 31st Annual Healthcare Conference, March 18, 2021 Exhibit 99.1 Forward-Looking Statements Disclaimer This presentation has been prepared by Cue Biopharma, Inc. ("we," "us," "our," "Cue" or the "Company") a
Read more →Evaluated initial observations in CUE-101 Phase 1 monotherapy dose escalation clinical trial for treatment of human papilloma virus positive recurrent/metastatic head and neck squamous cell carcinoma (HPV+ R/M HNSCC), which demonstrated tolerability and generated encouraging emer
Read more →CAMBRIDGE, Mass., March 15, 2021 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectively engage and modulate targeted T cells directly within the patient’s body, an
Read more →CAMBRIDGE, Mass., March 01, 2021 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectively engage and modulate targeted T cells within the patient’s body, announced t
Read more →CAMBRIDGE, Mass., Feb. 25, 2021 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectively engage and modulate targeted T cells within the patient’s body, announced to
Read more →CAMBRIDGE, Mass., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectively engage and modulate targeted T cells within the patient’s body, announced to
Read more →Appointment to strengthen clinical development capabilities with a strategic and visionary immunotherapy leader as Cue Biopharma advances its pipeline of drug development programs CAMBRIDGE, Mass., Feb. 17, 2021 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-s
Read more →CAMBRIDGE, Mass., Feb. 08, 2021 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectively engage and modulate targeted T cells within the patient’s body, announced to
Read more →CAMBRIDGE, Mass., Nov. 23, 2020 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectively engage and modulate targeted T cells within the patient’s body, announced to
Read more →CAMBRIDGE, Mass., Nov. 19, 2020 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells within the patient’s body, announced today that
Read more →CAMBRIDGE, Mass., Nov. 17, 2020 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectively engage and modulate targeted T cells within the patient’s body, provided a b
Read more →CAMBRIDGE, Mass., Nov. 11, 2020 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells within the patient’s body, announced today that
Read more →CAMBRIDGE, Mass., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells within the patient’s body, announced today three
Read more →CAMBRIDGE, Mass., Oct. 19, 2020 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells within the body, announced today three poster pr
Read more →Appointment augments board capabilities with a seasoned business development executive as Cue Biopharma executes its next stage of corporate development CAMBRIDGE, Mass., Sept. 17, 2020 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ: CUE), a clinical-stage biopharmaceutical com
Read more →Novel positron emission tomography approach demonstrates the ability of Immuno-STAT based scaffolds to selectively engage tissue-resident T cells including intratumoral T cells of defined specificity CAMBRIDGE, Mass., Sept. 15, 2020 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDA
Read more →CAMBRIDGE, Mass., Sept. 03, 2020 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells within the body, announced today it will presen
Read more →CAMBRIDGE, Mass., Aug. 31, 2020 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells within the body, provided a business update for
Read more →CAMBRIDGE, Mass., Aug. 24, 2020 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells within the body, announced today a poster presen
Read more →CUE-101 advances to cohort 5 following Safety Review Committee assessment of expanded cohort 4 Cohort 5 is fully enrolled, with first patient having been dosed on July 20 Additional patients to be enrolled in cohort 4 to further characterize pharmacodynamics and clinical activi
Read more →- Novel insights into receptor binding events and interfaces have led to generation of selective molecules with unique biochemical and functional properties through an effort led by Dr. Steven Almo at Albert Einstein College of Medicine - Enhances Cue Biopharma’s ability to engi
Read more →Patient enrollment and data generation remain on schedule with 13 patients having received CUE-101 to date and enrollment continues per protocol to identify a recommended Phase 2 dose Dose-proportional increases in drug exposure combined with observations demonstrating pharmacod
Read more →Nasdaq: CUE Corporate Presentation Immune Responses, On Cue Jefferies Virtual Healthcare Conference | June 4, 2020 Exhibit 99 Forward-Looking Statements This presentation has been prepared by Cue Biopharma, Inc. ("we," "us," "our," "Cue" or the "Company") and is made for infor
Read more →CAMBRIDGE, Mass., May 28, 2020 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells within the body, announced today it will present
Read more →Cue Biopharma Reports First Quarter 2020 Results, Updates of CUE-101 Phase 1 Dose Escalation Study and Recent Business Highlights CAMBRIDGE, Mass., May 19, 2020 Cue Biopharma, Inc. (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectabl
Read more →CAMBRIDGE, Mass., May 18, 2020 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells within the body, announced today a poster present
Read more →Collaboration to Study Immuno-STAT Biologics on T Cell Immunological Synapse Formation Using the IL-2-Based CUE-100 Series CAMBRIDGE, Mass., May 14, 2020 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class o
Read more →- Ongoing Phase 1 dose escalation and expansion study with CUE-101 as a monotherapy in post first-line recurrent/metastatic HNSCC patients to be amended to include combination of CUE-101 with standard of care KEYTRUDA as first-line therapy - Preliminary data from early patient c
Read more →Cue Biopharma Reports Fourth Quarter and Full Year 2019 Financial Results and Recent Business Highlights CAMBRIDGE, Mass., March 17, 2020 Cue Biopharma, Inc. (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectiv
Read more →Nasdaq: CUE | March 2020 Corporate Presentation Immune Responses, On Cue Cowen & Co. 40th Annual Healthcare Conference | March 2, 2020 EXHIBIT 99 Forward-Looking Statements This presentation has been prepared by Cue Biopharma, Inc. ("we," "us," "our," "Cue" or the "Company") a
Read more →CAMBRIDGE, Mass., Feb. 26, 2020 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells within the body, announced today it will present
Read more →Presentation Provides Update on Immuno-STAT Platform Demonstrating Selective Modulation of Targeted T cells in Preclinical Models CAMBRIDGE, Mass., Feb. 19, 2020 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel
Read more →CAMBRIDGE, Mass., Feb. 12, 2020 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells within the body, announced today Dr. Mary Simcox
Read more →CAMBRIDGE, Mass., Jan. 21, 2020 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells within the body, announced today the publication
Read more →CAMBRIDGE, Mass., Dec. 02, 2019 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells within the body, announced today Dr. John Ross,
Read more →Cue Biopharma Reports Third Quarter 2019 Financial Results and Recent Business Highlights CAMBRIDGE, Mass., November 12, 2019 Cue Biopharma, Inc. (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively engage a
Read more →CAMBRIDGE, Mass., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells within the body, announced today that it will pr
Read more →CAMBRIDGE, Mass., Oct. 30, 2019 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells within the body, announced today that it will de
Read more →CAMBRIDGE, Mass., Oct. 15, 2019 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells within the body, announced today that it will pr
Read more →CAMBRIDGE, Mass., Oct. 09, 2019 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ: CUE) a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells within the body, announced today changes to its b
Read more →CAMBRIDGE, Mass., Oct. 09, 2019 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells within the body, announced today it is scheduled
Read more →CAMBRIDGE, Mass., Oct. 07, 2019 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ: CUE) a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells within the body, announced today the promotion of
Read more →CAMBRIDGE, Mass., Oct. 02, 2019 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells within the body, announced today that it will pr
Read more →CAMBRIDGE, Mass., Sept. 30, 2019 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells within the body, announced today that on Septem
Read more →CAMBRIDGE, Mass., June 03, 2019 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc., (NASDAQ: CUE) an innovative clinical stage immunotherapy company developing a novel, proprietary class of biologics engineered to selectively modulate the human immune system to treat cancer, autoimmune and
Read more →Initiation of First-in-Human Phase 1 Clinical Trial for Monotherapy Dose Escalation Earns $2.5 Million Milestone for IND Acceptance from Partner LG Chem Life Sciences CAMBRIDGE, Mass., May 16, 2019 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc., (NASDAQ: CUE), an innovative clinical s
Read more →CAMBRIDGE, Mass., April 08, 2019 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ: CUE), an innovative immunotherapy company developing a novel, proprietary class of biologics engineered to selectively modulate the human immune system to treat cancer, autoimmune and chronic infect
Read more →CAMBRIDGE, Mass., March 14, 2019 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc., (NASDAQ: CUE) an innovative immunotherapy company developing a novel, proprietary class of biologics engineered to selectively modulate the human immune system to treat cancer, autoimmune and chronic infect
Read more →CAMBRIDGE, Mass., Feb. 11, 2019 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc., (NASDAQ: CUE) an innovative immunotherapy company developing a novel, proprietary class of biologics engineered to selectively modulate the human immune system to treat cancer, autoimmune and chronic infecti
Read more →CAMBRIDGE, Mass., Jan. 16, 2019 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc., (NASDAQ: CUE) an innovative immunotherapy company developing a novel, proprietary class of biologics engineered to selectively modulate the human immune system to treat cancer, autoimmune and chronic infecti
Read more →Cue Biopharma and LG Chem Life Sciences Announce WT1 as the Next Immuno-STAT Target in Oncology WT1 is a Well-Characterized Oncofetal Antigen, Expressed in Solid Tumors and Hematologic Malignancies CAMBRIDGE, Mass., Dec. 20, 2018 Cue Biopharma , Inc., (NASDAQ: CUE) an innovat
Read more →CUE-101 Demonstrates Selective Binding and Preferential Activation/Expansion of Antigen-specific T Cells, Inhibition of Tumor Growth as Monotherapy and in Combination with a PD-1 Inhibitor CAMBRIDGE, Mass., Nov. 09, 2018 (GLOBE NEWSWIRE) -- Cue Biopharma™, Inc., (NASDAQ: CUE) an
Read more →Cue Biopharma Announces Strategic Collaboration with LG Chem Life Sciences for Immuno-STAT Biologics in Oncology Collaboration Expands Development and Manufacturing of Immuno-STAT Biologics and Broadens Coverage of Patient Populations CAMBRIDGE, Mass., Nov. 8, 2018 Cue Biopha
Read more →CAMBRIDGE, Mass., Oct. 30, 2018 (GLOBE NEWSWIRE) -- Cue Biopharma™, Inc., (NASDAQ: CUE) an innovative immunotherapy company developing a novel, proprietary class of biologics engineered to selectively modulate the human immune system to treat cancer, autoimmune and chronic infect
Read more →Collaboration Expands Platform’s Reach Beyond Cancer and Autoimmune Disease to Address T cell Exhaustion in Chronic Infectious Diseases CAMBRIDGE, Mass., Oct. 17, 2018 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc., (NASDAQ: CUE) an innovative immunotherapy company developing a novel,
Read more →CAMBRIDGE, Mass., Oct. 03, 2018 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc., (NASDAQ: CUE) an innovative immunotherapy company developing a novel, proprietary class of biologics engineered to selectively modulate the human immune system to treat cancer, autoimmune and chronic infecti
Read more →CAMBRIDGE, Mass., Aug. 14, 2018 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc., (NASDAQ: CUE) an innovative immunotherapy company developing a novel, proprietary class of biologics engineered to selectively modulate the human immune system to treat cancer, autoimmune and chronic infecti
Read more →CAMBRIDGE, Mass., Aug. 03, 2018 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc., (NASDAQ:CUE) a next-generation immunotherapy company developing a novel, proprietary class of biologics engineered to selectively modulate the human immune system to treat cancer, autoimmune and chronic infe
Read more →CAMBRIDGE, Mass., July 24, 2018 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc., (NASDAQ:CUE) a next-generation immunotherapy company developing a novel, proprietary class of biologics engineered to selectively modulate the human immune system to treat cancer, autoimmune and chronic infe
Read more →CAMBRIDGE, Mass., July 12, 2018 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc., an immunotherapy company developing a novel, proprietary class of biologics engineered to selectively modulate the human immune system to treat cancer and autoimmune diseases, today announced progress in its
Read more →Cue Biopharma Produces Immuno-STATTM Biologic Candidate for Treatment of Autoimmune Disease Under Collaboration and License Agreement with Merck CAMBRIDGE, MA, July. 12, 2018 Cue Biopharma, Inc., an immunotherapy company developing a novel, proprietary class of biologics engin
Read more →CAMBRIDGE, Mass., June 28, 2018 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc., (NASDAQ:CUE) a next-generation immunotherapy company developing a novel, proprietary class of biologics engineered to selectively modulate the human immune system to treat cancer and autoimmune diseases, ann
Read more →Notice of Change of Location and Time of Annual Meeting of Stockholders To the Stockholders of Cue Cue Biopharma, Inc. has changed the location of its annual meeting of stockholders scheduled for Tuesday, June 12, 2018 (the 2018 Annual Meeting ). The meeting date, time and re
Read more →Copyright 2018. Cue Biopharma Corporate Overview Nasdaq: CUE May 17th, 2018 Exhibit 99 Forward Looking Statement This press presentation contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Se
Read more →CAMBRIDGE, Mass., April 25, 2018 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ:CUE), an innovative immunotherapy company developing a novel, proprietary class of biologics engineered to selectively modulate the human immune system to treat a broad range of cancer and autoimmune
Read more →CAMBRIDGE, Mass., April 05, 2018 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc., (NASDAQ:CUE) an immunotherapy company developing a novel, proprietary class of biologics engineered to selectively modulate the human immune system to treat cancer and autoimmune diseases, announced today t
Read more →